Development of novel therapy for malignant mesothelioma by controllingADCC activity.

通过控制 ADCC 活性开发恶性间皮瘤的新疗法。

• 批准号: 22590863
• 负责人: SHIMIZU Eiji
• 金额: $ 2.75万
• 依托单位: Tottori University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22590863/
• 关键词: 胸膜中皮腫; 分子標的治療

Most patients with malignant pleural mesothelioma (MPM) have a history of exposure to carcinogenic asbestos fibers, and the latent period of this disease is more than 40 years. Therefore, the numbers of the patients are now still increasing. Cetuximab is a chimeric mouse-human antibody directed against the extracellular domain of EGFRand has been shown remarkable effects for colorectal cancer and head and neck cancer. However, no published in vitro or in vivo studies have focused on the effect of cetuximab against MPM. In the present study, we found that cetuximab has potent anti-tumor activity against MPM in combination with the methods to enhance its immunological function, antibody-dependent cellular cytotoxicity (ADCC) activity. Our data indicate the important role of ADCC activity in the mechanism of action of cetuximab and underscore the promising potential of cetuximab as a new class of therapeutic agent for use against MPM.

大多数恶性胸膜间皮瘤（MPM）患者有致癌石棉纤维接触史，本病潜伏期长达40年以上。因此，目前患者数量仍在不断增加。西妥昔单抗是一种针对EGFR胞外域的嵌合鼠人抗体，已显示出对结直肠癌和头颈癌的显着疗效。然而，尚未发表的体外或体内研究关注西妥昔单抗对 MPM 的作用。在本研究中，我们发现西妥昔单抗与增强其免疫功能、抗体依赖性细胞毒性（ADCC）活性的方法相结合，具有针对MPM的有效抗肿瘤活性。我们的数据表明 ADCC 活性在西妥昔单抗作用机制中的重要作用，并强调了西妥昔单抗作为一类新型治疗剂用于对抗 MPM 的前景。

项目成果

Diagnostic and Prognostic Impact of Serum Soluble UL16-Bin ding Protein 2 in Lung Cancer Patients

血清可溶性 UL16 结合蛋白 2 对肺癌患者的诊断和预后影响

• 发表时间: 2012
• 影响因子: 5.7
• 作者: Yamaguchi K; Shimizu E; et al
• 通讯作者: et al

Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity

EGFR 突变肺癌细胞中缺乏 AKT 激活是西妥昔单抗敏感性的新标志

• 发表时间: 2012
• 影响因子: 3.6
• 作者: Takata M; Chikumi H; Miyake N; Adachi K; Kanamori Y; Yamasaki A; Igishi T; Burioka N; Nanba E; Shimizu E
• 通讯作者: Shimizu E

Circulating serum ULBP2 in patients with various lung diseases

各种肺部疾病患者循环血清ULBP2

• 发表时间: 2012
• 作者: Kinoshita N; Chikumi H; Yamaguchi K; Takata M; Nakamoto M; Kodani M; Matsumoto S; Kawasaki Y; Tadashi I; Shimizu E
• 通讯作者: Shimizu E